Released on Wednesday, the proposal aims to loosen regulations on developing value-based purchasing (VBP) arrangements, encourages innovation, and empowers "states, private payers, and manufacturers to pay for prescription drugs based on clinical outcomes."
The rule gives states flexibility to enter innovative value-based...
